Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Moderna has asked the FDA for emergency use authorisation for a fourth dose of its mRNA COVID-19 vaccine SpikeVax ... Pfizer's application was from an open-label study in Israel involving ...

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

Moderna has been rebuked by ... not be seen as anything other than promotion of Spikevax,” the PMCPA said. The presentation also included off-label data. Molly Kingsley, from the campaign ...

According to the lawsuit, the development of Moderna’s COVID-19 vaccine, Spikevax, depended on key technological advancements made at Northwestern. Also Read: Alnylam’s Concedes Its Patent ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

This is a major concern for Moderna because it could mean that they used a GSK technology to produce their COVID-19 vaccine, Spikevax, as well as their RSV vaccine, mResvia. GSK asserts that ...

The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.